During the past decade, Metro Minnesota Community Oncology Research Consortium conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 101 clinical trials were completed, i.e. on average, 240.5% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 54 clinical trials were completed. i.e. 450% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Metro Minnesota Community Oncology Research Consortium" #1 sponsor was "National Cancer Institute (NCI)" with 79 trials, followed by "Gynecologic Oncology Group" with 11 trials sponsored, "SWOG Cancer Research Network" with 11 trials sponsored, "Academic and Community Cancer Research United" with 8 trials sponsored and "Alliance Foundation Trials, LLC." with 8 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Metro Minnesota Community Oncology Research Consortium" #1 collaborator was "National Cancer Institute (NCI)" with 38 trials as a collaborator, "NRG Oncology" with 13 trials as a collaborator, "SWOG Cancer Research Network" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 6 trials as a collaborator and "NCIC Clinical Trials Group" with 5 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "Metro Minnesota Community Oncology Research Consortium" are "Recurrent Breast Carcinoma" (8 trials), "Clear Cell Renal Cell Carcinoma" (7 trials), "Ovarian Endometrioid Adenocarcinoma" (7 trials), "Ovarian Seromucinous Carcinoma" (7 trials) and "Recurrent Ovarian Carcinoma" (7 trials). Many other conditions were trialed in "Metro Minnesota Community Oncology Research Consortium" in a lesser frequency.

Most popular intervention types in "Metro Minnesota Community Oncology Research Consortium" are "Drug" (125 trials), "Other" (104 trials), "Biological" (56 trials), "Procedure" (18 trials) and "Radiation" (13 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (78 trials), "Quality-of-Life Assessment" (38 trials), "Bevacizumab" (26 trials), "Paclitaxel" (25 trials) and "Carboplatin" (19 trials). Other intervention names were less common.

The vast majority of trials in "Metro Minnesota Community Oncology Research Consortium" are 108 trials for "All" genders, 37 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Metro Minnesota Community Oncology Research Consortium". undefined are not yet recruiting, 6 are recruiting, 58 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 63 completed trials in Metro Minnesota Community Oncology Research Consortium, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Metro Minnesota Community Oncology Research Consortium, 11 "Phase 1" clinical trials were conducted, 72 "Phase 2" clinical trials and 66 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".